Quarterly Activities/Appendix 4C Cash Flow Report
| Stock | Control Bionics Ltd (CBL.ASX) |
|---|---|
| Release Time | 31 Jul 2025, 9:15 a.m. |
| Price Sensitive | Yes |
Control Bionics delivers record year with 15% revenue growth
- Record year with $6m+ in unaudited sales revenue and $7m+ in total revenue
- Strong H2FY25 revenue growth in the US driven by HCPCS code adoption
- Discussions with potential US distribution partners well advanced
Control Bionics Limited (ASX: CBL) has announced its Activity Report and Appendix 4C for the quarter ended 30 June 2025. The company delivered a record year, with unaudited sales revenue growing 15% to over $6m and total revenue of more than $7m. The strong H2FY25 revenue growth in the US was driven by HCPCS code adoption, which will underpin further growth in the US, the company's largest addressable market. Discussions with multiple potential partners in the US are well advanced. In Australia, the company successfully delivered the Neuro Elite Athletics (NeuroBounce®) program, with all 5 athletes increasing their vertical jump height. The NeuroNode® Only distribution strategy is gaining strong momentum, with significant interest from distributors in multiple geographies. The company is also commercializing its NeuroStrip technology, which provides opportunities to enter new markets such as health diagnostics, sports performance and rehabilitation. Control Bionics remains focused on five key strategic priorities for FY26, including achieving profitability in core markets, scaling the NeuroNode business, expanding NeuroStrip, accelerating growth through partnerships and acquisitions, and building a high-performance organization.
The company expects continued improvement in net operating cash flows, with preliminary unaudited results for FY25 indicating an approximate 15% increase in operating revenue compared to the prior year. The company has also secured a short-term loan facility to provide immediate working capital support.
Control Bionics remains focused on five key strategic priorities for FY26, including achieving profitability in core markets, scaling the NeuroNode business, expanding NeuroStrip, accelerating growth through partnerships and acquisitions, and building a high-performance organization.